Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma

Fig. 1

The effect of rucaparib and olaparib on clonogenic survival. SK-N-BE(2c) (a) and UVW/NAT cells (b) were treated with various concentrations of rucaparib or olaparib. After 24 h treatment, clonogenic survival was assessed by clonogenic assay. Data are means ± SEM, n = 3; * p < 0.05, ** p < 0.01 compared to untreated control

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us